Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

Read on for a whirlwind, worldwide tour of recent personnel moves. A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

The deal adds to a rapidly-expanding pipeline of NASH candidates at Novo Nordisk, which also includes GLP-1 analogue semaglutide in phase 3 in combination with drugs from Gilead, a long-acting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

In fact, most contractors said developers are struggling to put deals together — same as in 2023 and 2024. A few of the reasons: still-elevated interest rates, higher labor and materials costs ...

As of 3:01:15 pm GMT+2. Market open.